1. Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology

   • Belén P. Solans
   • María Jesús Garrido
   • Iñaki F. Trocóniz

   Review Article 26 October 2019 Pages: 123 - 135

   

2. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review

   • Joshua P. Havens
   • Anthony T. Podany
   • Courtney V. Fletcher

   Review Article 02 November 2019 Pages: 137 - 154

   

3. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

   • Hanne Haahr
   • Tim Heise

   Review Article Open access 30 October 2019 Pages: 155 - 172

   

4. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature

   • Stan J. F. Hartman
   • Roger J. Brüggemann
   • Saskia N. de Wildt

   Systematic Review Open access 20 August 2019 Pages: 173 - 205

   

5. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

   • Julie M. Janssen
   • T. P. C. Dorlo
   • A. D. R. Huitema

   Original Research Article 16 July 2019 Pages: 207 - 216

   

6. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

   • Ken Ogasawara
   • Kathryn Newhall
   • Yan Li

   Original Research Article Open access 22 July 2019 Pages: 217 - 227

   

7. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

   • Carlos Pérez-Ruixo
   • Jonás Samuel Pérez-Blanco
   • Oliver Ackaert

   Original Research Article 20 August 2019 Pages: 229 - 244

   

8. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate^®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

   • Pierre Chelle
   • Cindy H. T. Yeung
   • Alfonso Iorio

   Original Research Article 22 August 2019 Pages: 245 - 256

   

9. Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus

   • Nienke J. Vet
   • Brenda C. M. de Winter
   • Matthijs de Hoog

   Original Research Article Open access 21 August 2019 Pages: 257 - 264

   

10. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

    • Axel Krebs-Brown
    • Alain Munafo
    • Claire Castello-Bridoux

    Letter to the Editor Open access 05 December 2019 Pages: 265 - 267

    

11. Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

    • D. Concordet
    • P. Gandia
    • P. L. Toutain

    Letter to the Editor Open access 05 December 2019 Pages: 269 - 271

12. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

    • Patrick Nicolas

    Letter to the Editor 05 December 2019 Pages: 273 - 275

13. Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

    • Didier Concordet
    • Peggy Gandia
    • Pierre-Louis Toutain

    Letter to the Editor Open access 05 December 2019 Pages: 277 - 279

14. Comment on “Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?”

    • Yang Yu
    • Marc Maliepaard

    Letter to the Editor 05 December 2019 Pages: 281 - 282

15. Authors’ Reply to Yu et al.: “Levothyrox^® New and Old Formulations: Are They Switchable for Millions of Patients?”

    • Didier Concordet
    • Peggy Gandia
    • Pierre-Louis Toutain

    Letter to the Editor Open access 05 December 2019 Pages: 283 - 285